NL8100503A - Indomethacinebevattend geneesmiddel voor topicaal gebruik. - Google Patents
Indomethacinebevattend geneesmiddel voor topicaal gebruik. Download PDFInfo
- Publication number
- NL8100503A NL8100503A NL8100503A NL8100503A NL8100503A NL 8100503 A NL8100503 A NL 8100503A NL 8100503 A NL8100503 A NL 8100503A NL 8100503 A NL8100503 A NL 8100503A NL 8100503 A NL8100503 A NL 8100503A
- Authority
- NL
- Netherlands
- Prior art keywords
- indomethacin
- polyethylene glycol
- ether
- mixture
- alkyl
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title claims description 10
- 229940126601 medicinal product Drugs 0.000 title claims description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 52
- 229960000905 indomethacin Drugs 0.000 claims description 26
- 229920001223 polyethylene glycol Polymers 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims description 5
- 230000009974 thixotropic effect Effects 0.000 claims description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000013543 active substance Substances 0.000 description 5
- 229960001047 methyl salicylate Drugs 0.000 description 5
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 3
- 208000025978 Athletic injury Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000037374 absorbed through the skin Effects 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002848 endoanesthetic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3006024A DE3006024C2 (de) | 1980-02-18 | 1980-02-18 | Topisches, Indomethacin enthaltendes Arzneimittel in Salbenform |
| DE3006024 | 1980-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8100503A true NL8100503A (nl) | 1981-09-16 |
Family
ID=6094913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8100503A NL8100503A (nl) | 1980-02-18 | 1981-02-03 | Indomethacinebevattend geneesmiddel voor topicaal gebruik. |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS6024764B2 (enExample) |
| AT (1) | AT373148B (enExample) |
| BE (1) | BE887541A (enExample) |
| CH (1) | CH645541A5 (enExample) |
| DE (1) | DE3006024C2 (enExample) |
| ES (1) | ES500421A0 (enExample) |
| FR (1) | FR2475897A1 (enExample) |
| GB (1) | GB2069334B (enExample) |
| IT (1) | IT1136564B (enExample) |
| NL (1) | NL8100503A (enExample) |
| SE (1) | SE447060B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815940A (ja) * | 1981-07-23 | 1983-01-29 | Eisai Co Ltd | ポリプレニル系化合物およびその製造方法ならびにそれを含有する医薬 |
| JPS59227818A (ja) * | 1983-06-09 | 1984-12-21 | Mitsubishi Chem Ind Ltd | ゲル状軟膏剤 |
| CH643138A5 (de) * | 1983-08-29 | 1984-05-30 | Mepha Ag | Indomethacin enthaltende, gelartige salbe. |
| KR930000029B1 (ko) * | 1984-03-14 | 1993-01-06 | 제롬 꼬르비에르 | N-아실 인돌류 활성성분의 용해방법 |
| JPS60224638A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 経皮吸収促進剤およびこれを含有する外用剤 |
| JPH07112984B2 (ja) * | 1989-04-28 | 1995-12-06 | 久光製薬株式会社 | 泡状エアゾール製剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3624197A (en) * | 1969-09-04 | 1971-11-30 | Philip Schain | Water-soluble tissue infiltrating and embedding compositions |
| BE756975A (fr) * | 1970-06-09 | 1971-04-02 | Merck & Co Inc | Suppositoires |
| US4011313A (en) * | 1974-06-07 | 1977-03-08 | Syntex (U.S.A.) Inc. | Medicament preparations |
| JPS5320417A (en) * | 1976-08-10 | 1978-02-24 | Yamanouchi Pharmaceut Co Ltd | New composition of preparation for rectal application |
| GB2023000B (en) * | 1978-06-17 | 1982-10-13 | Kowa Co | Antinflammatory analgesic gelled ointments |
-
1980
- 1980-02-18 DE DE3006024A patent/DE3006024C2/de not_active Expired
-
1981
- 1981-01-29 GB GB8102674A patent/GB2069334B/en not_active Expired
- 1981-01-29 SE SE8100623A patent/SE447060B/sv not_active IP Right Cessation
- 1981-02-02 CH CH67181A patent/CH645541A5/de not_active IP Right Cessation
- 1981-02-03 NL NL8100503A patent/NL8100503A/nl not_active Application Discontinuation
- 1981-02-05 AT AT0051381A patent/AT373148B/de not_active IP Right Cessation
- 1981-02-17 BE BE0/203809A patent/BE887541A/fr not_active IP Right Cessation
- 1981-02-17 FR FR8103119A patent/FR2475897A1/fr active Granted
- 1981-02-18 JP JP56021633A patent/JPS6024764B2/ja not_active Expired
- 1981-02-18 ES ES500421A patent/ES500421A0/es active Granted
- 1981-02-18 IT IT19824/81A patent/IT1136564B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| ATA51381A (de) | 1982-06-15 |
| AT373148B (de) | 1983-12-27 |
| GB2069334B (en) | 1983-10-19 |
| DE3006024A1 (de) | 1981-08-20 |
| CH645541A5 (de) | 1984-10-15 |
| ES8201826A1 (es) | 1982-01-16 |
| FR2475897B1 (enExample) | 1984-02-10 |
| FR2475897A1 (fr) | 1981-08-21 |
| GB2069334A (en) | 1981-08-26 |
| IT1136564B (it) | 1986-09-03 |
| IT8119824A0 (it) | 1981-02-18 |
| JPS6024764B2 (ja) | 1985-06-14 |
| JPS56135413A (en) | 1981-10-22 |
| ES500421A0 (es) | 1982-01-16 |
| DE3006024C2 (de) | 1983-08-04 |
| BE887541A (fr) | 1981-06-15 |
| SE447060B (sv) | 1986-10-27 |
| SE8100623L (sv) | 1981-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4560549A (en) | Method of relieving pain and inflammatory conditions employing substituted salicylamides | |
| US4742083A (en) | Method of relieving pain and inflammatory conditions employing substituted salicylamides | |
| CA1280366C (en) | Topical antimicrobial pharmaceutical composition comprising a silver compound and an azole | |
| US5985860A (en) | System for transdermal delivery of pain relieving substances | |
| KR970704453A (ko) | 통증 제어용 신규 제약 제제(New Pharmaceutical Preparation for Pain Management) | |
| JP4449213B2 (ja) | 坐剤用組成物 | |
| JPS63145238A (ja) | １−置換イミダゾールおよびｎｓａｉｄを含む座瘡治療のための局所用配合物 | |
| CZ20014289A3 (cs) | Nové pouľití sloučenin jako antibakteriálních činidel | |
| JPS6261917A (ja) | アリ−ルプロピオン酸誘導体の経皮的に吸収しうる含水製剤とその製造方法 | |
| EP0055029B1 (en) | Preparations for the treatment of dermatoses | |
| AR029190A1 (es) | Composiciones que contienen derivados del acido hidroxieicosatetraenoico y uso para la manufactura de un medicamento en el tratamiento de trastornos del ojo seco | |
| US4725590A (en) | Method of relieving pain and inflammatory conditions employing substituted salicylamides | |
| NL8100503A (nl) | Indomethacinebevattend geneesmiddel voor topicaal gebruik. | |
| US4614741A (en) | Depot antiinflammatory agents | |
| JP3179501B2 (ja) | 抗炎症薬として有用なイオウ含有ジ−ｔ−ブチルフェノール化合物 | |
| MXPA02005149A (es) | Uso de derivados de pleuromutilina para el tratamiento transdermico de enfermedades bacterianas. | |
| WO2008115656A1 (en) | Novel burn treatment composition | |
| CZ868686A3 (en) | Primicin-containing colloidal elementary gel, and process for preparing thereof | |
| CA2046412A1 (en) | Treatment of inflammatory diseases with polyoxyethylenesorbitan mono-higher-fatty acid esters | |
| US20100144780A1 (en) | Salts and Mixture of 9-Oxoacridine-10-Acetic Acid with 1-Alkylamino-1-Desoxy-Polyols, Pharmaceutical Compositions Containing Said Agents and Treatment Methods | |
| EP0984012A2 (en) | Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties | |
| KR100297212B1 (ko) | 직장투여용조성물 | |
| PT1156829E (pt) | ''formulação estável contendo fumagilina'' | |
| Verma et al. | Emulgel: a recent technique for topical drug delivery-a review | |
| JPH0276816A (ja) | 外用剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |